Table 2.
Univariate analysis of clinical variables associated with overall survival
| Variable | Univariate analysis | |
|---|---|---|
| HR (95% CI) | P value | |
| Age (≤ 56 vs. > 56) | 0.986 (0.639–1.522) | 0.951 |
| Gender (female vs. male) | 0.710 (0.224–2.254) | 0.561 |
| Body mass index (kg/m2) (≤ 21.3 vs. > 21.3) | 1.699 (1.096–2.634) | 0.018 |
| Body surface area (m2) (≤1.65 vs. > 1.65) | 1.614 (1.042–2.502) | 0.032 |
| ECOG performance status (0–1 vs. 2–3) | 0.376 (0.210–0.672) | 0.001 |
| Stage (I&II vs. III) | 0.223 (0.055–0.910) | 0.036 |
| Tumor location (U involved vs. others) | 0.733 (0.473–1.136) | 0.165 |
| Smoking (no vs. yes) | 0.744 (0.358–1.547) | 0.428 |
| Alcohol (no vs. yes) | 0.529 (0.214–1.310) | 0.169 |
| Hypertension (no vs. yes) | 1.002 (0.587–1.710) | 0.994 |
| Diabetes (no vs. yes) | 0.624 (0.335–1.160) | 0.136 |
| Cardiovascular disease (no vs. yes) | 0.919 (0.336–2.518) | 0.870 |
| Heart volume (ml) (≤592 vs > 592) | 1.468 (0.947–2.276) | 0.086 |
| Chemotherapy regimen (F vs. NF) | 0.318 (0.150–0.673) | 0.003 |
| Radiation dose (Gy) (≤ 61.2 vs. > 61.2) | 1.451 (0.924–2.280) | 0.106 |
| PTV prescribed to 36 Gy (ml) (continuous) | 1.001 (1.000–1.001) | 0.055 |
| PTV prescribed to 50 Gy (ml) (continuous) | 1.001 (1.000–1.002) | 0.004 |
Abbreviations: ECOG Eastern Cooperative Oncology Group, F Fluoropyrimidine-based, NF Not fluoropyrimidine-based, PTV Planning target volume, U Upper thoracic and cervical esophagus